1Department of Pathology, Peking University Shenzhen Hospital, Shenzhen, China
2Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
3Department of Pathology, Kwong Wah Hospital, Hong Kong
4Department of Pathology, Tuen Mun Hosiptal, Hong Kong
Copyright © 2019 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Proportion of PELPL1+ve cells |
No. of cases |
|||||
---|---|---|---|---|---|---|
Mean | Median | Low | Focal | Diffuse | Total | |
Breasta) | 51.9 | 70 | 317 (29.5) | 21 (2.0) | 735 (68.5) | 1,073 |
Lunga) | 34.8 | 0 | 160 (50.8) | 9 (2.9) | 146 (46.3) | 315 |
Ovarya) | 32.4 | 0 | 64 (57.7) | 1 (0.9) | 46 (41.4) | 111 |
Colorectal | 8.7 | 0 | 179 (86.5) | 3 (1.4) | 25 (12.1) | 207 |
Gastric | 2.3 | 0 | 124 (94.7) | 5 (3.8) | 2 (1.5) | 131 |
RCC | 7.9 | 0 | 84 (85.7) | 6 (6.1) | 8 (8.1) | 98 |
Values are presented as number (%). PELP1, proline, glutamic acid, and leucine-rich protein 1; LVI, lymphovascular invasion; FF, fibrotic focus; HER2-OE, human epidermal growth factor receptor 2 overexpression; BLBC, basal like breast cancer; 5NP, quintuple negative; SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; EGFR, epidermal growth factor receptor; CK, cytokeratin; MGB, mammaglobin; GCDFP-15, gross cystic disease fluid protein 15.
Values are presented as number (%). PELP1, proline, glutamic acid, and leucine-rich protein 1; GCDFP-15, gross cystic disease fluid protein 15; MGB, mammaglobin; HER2-OE, human epidermal growth factor receptor 2 overexpression; TNBC, triple negative breast cancer; BLBC, basal like breast cancer; 5NP, quintuple negative.
Backwald method was used for the analysis. Factors included in the initial steps included age, grade, LVI, pT, pN, Ki67, HER2, AR, and PELP1 status. LVI, Ki67, HER2, AR and PELP1 were analyzed as categorical variables. The absence of LVI, Ki67 low, HER2 negativity, AR negativity, and PELP1 low status were used as references in their categories. DFS, disease free survival; BCSS, breast cancer specific survival; HR, hazard ratio; CI, confidence interval; PELP1, proline, glutamic acid, and leucine-rich protein 1; LVI, lymphovascular invasion; HER2, human epidermal growth factor receptor 2; AR, androgen receptor.
Proportion of PELPL1+ve cells |
No. of cases |
|||||
---|---|---|---|---|---|---|
Mean | Median | Low | Focal | Diffuse | Total | |
Breast |
51.9 | 70 | 317 (29.5) | 21 (2.0) | 735 (68.5) | 1,073 |
Lung |
34.8 | 0 | 160 (50.8) | 9 (2.9) | 146 (46.3) | 315 |
Ovary |
32.4 | 0 | 64 (57.7) | 1 (0.9) | 46 (41.4) | 111 |
Colorectal | 8.7 | 0 | 179 (86.5) | 3 (1.4) | 25 (12.1) | 207 |
Gastric | 2.3 | 0 | 124 (94.7) | 5 (3.8) | 2 (1.5) | 131 |
RCC | 7.9 | 0 | 84 (85.7) | 6 (6.1) | 8 (8.1) | 98 |
Clincopathological feature | PELP1 |
Total | p-value | ||
---|---|---|---|---|---|
Low | Focal | Diffuse | |||
Grade | |||||
1 | 46 (28.4) | 6 (3.7) | 110 (67.9) | 162 | 0.903 |
2 | 127 (30.1) | 8 (18.9) | 287 (68.0) | 422 | |
3 | 144 (29.5) | 7 (1.4) | 338 (69.1) | 489 | |
LVI | |||||
Absent | 216 (29.4) | 15 (2.0) | 504 (68.6) | 735 | 0.723 |
Present | 88 (30.7) | 5 (1.7) | 194 (67.6) | 287 | |
FF | |||||
Absent | 216 (27.3) | 14 (17.7) | 561 (70.9) | 791 | 0.001 |
Present | 98 (37.4) | 7 (26.7) | 157 (29.9) | 262 | |
pT | |||||
1 | 116 (27.0) | 11 (2.6) | 303 (70.4) | 430 | 0.125 |
2 | 174 (31.1) | 9 (1.6) | 376 (67.3) | 559 | |
3 | 19 (34.5) | 0 | 36 (65.5) | 55 | |
4 | 6 (37.5) | 0 | 10 (62.5) | 16 | |
pN | |||||
0 | 149 (28.4) | 11 (2.1) | 364 (69.5) | 524 | 0.309 |
1 | 94 (30.9) | 5 (1.7) | 205 (67.4) | 304 | |
2 | 36 (27.9) | 1 (0.8) | 92 (71.3) | 129 | |
3 | 31 (36.1) | 2 (2.3) | 53 (61.6) | 86 | |
Molecular subtype | |||||
Luminal A | 166 (34.1) | 11 (2.3) | 310 (63.6) | 487 | 0.012 |
Luminal B | 72 (22.4) | 4 (1.2) | 246 (76.4) | 322 | |
HER2-OE | 31 (29.2) | 2 (1.9) | 73 (68.9) | 106 | |
BLBC | 16 (24.3) | 2 (3.0) | 48 (72.7) | 66 | |
5NP | 32 (39.0) | 2 (2.5) | 48 (58.5) | 82 | |
Age (yr) | |||||
Mean±SD | 56.4±13.1 | 57.0±14.5 | 53.8±12.4 | 54.7±12.7 | 0.007 |
Range | 28-97 | 35-94 | 22-91 | ||
Size (cm) | |||||
Mean±SD | 2.75±1.43 | 2.27±1.10 | 2.66±1.48 | 2.68±4.46 | 0.204 |
Range | 0.2-10.1 | 0.8-4.2 | 0.2-13.0 | ||
ER | |||||
Negative | 95 (30.1) | 9 (2.8) | 212 (67.1) | 316 | 0.702 |
Positive | 222 (29.5) | 12 (1.6) | 518 (68.9) | 752 | |
PR | |||||
Negative | 114 (31.7) | 7 (1.9) | 239 (66.4) | 360 | 0.318 |
Positive | 202 (28.7) | 14 (2.0) | 488 (69.3) | 704 | |
AR | |||||
Negative | 221 (39.9) | 12 (2.2) | 321 (57.9) | 554 | < 0.001 |
Positive | 93 (18.5) | 9 (1.8) | 400 (79.7) | 502 | |
Ki67 | |||||
Low | 266 (34.1) | 16 (2.1) | 497 (63.8) | 779 | < 0.001 |
High | 48 (17.1) | 5 (1.8) | 228 (81.1) | 281 | |
HER2 | |||||
Negative | 267 (31.1) | 17 (2.0) | 575 (66.9) | 859 | 0.045 |
Positive | 50 (24.0) | 4 (1.9) | 154 (74.1) | 208 | |
EGFR | |||||
Negative | 306 (30.6) | 21 (2.1) | 674 (67.3) | 1,001 | 0.001 |
Positive | 6 (11.1) | 0 | 48 (88.9) | 54 | |
CK5/6 | |||||
Negative | 295 (30.9) | 18 (1.9) | 641 (67.2) | 954 | 0.015 |
Positive | 21 (19.3) | 3 (2.7) | 85 (78.0) | 109 | |
CK14 | |||||
Negative | 305 (30.6) | 19 (1.9) | 673 (67.5) | 997 | 0.017 |
Positive | 10 (15.9) | 2 (3.2) | 51 (80.9) | 63 | |
Vimentin | |||||
Negative | 281 (30.8) | 17 (1.9) | 615 (67.3) | 913 | 0.070 |
Positive | 33 (22.9) | 4 (2.8) | 107 (74.3) | 144 | |
P-cadherin | |||||
Negative | 265 (32.9) | 12 (1.5) | 528 (65.6) | 805 | 0.001 |
Positive | 50 (20.7) | 8 (3.3) | 184 (76.0) | 242 | |
GATA3 | |||||
Low | 70 (38.0) | 4 (2.2) | 110 (59.8) | 184 | 0.012 |
Focal/Diffuse | 243 (28.8) | 16 (1.9) | 586 (69.3) | 845 | |
MGB | |||||
Low | 96 (24.1) | 7 (1.8) | 295 (74.1) | 398 | 0.302 |
Focal/Diffuse | 75 (24.5) | 6 (2.0) | 225 (73.5) | 306 | |
GCDFP-15 | |||||
Low | 226 (30.1) | 12 (1.6) | 514 (68.3) | 752 | 0.763 |
Focal/Diffuse | 84 (28.5) | 8 (2.7) | 203 (68.8) | 295 |
PELP1 |
GCDFP15 |
MGB |
GATA3 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Low | Focal | Diffuse | Low | Focal | Diffuse | Low | Focal | Diffuse | Low | Focal | Diffuse | |
Overall | 317 (29.5) | 21 (2.0) | 735 (68.5) | 817 (72.0) | 193 (17.0) | 125 (11.0) | 443 (56.6) | 237 (30.3) | 103 (13.1) | 191 (17.6) | 87 (8.0) | 810 (74.4) |
Molecular subtypes | ||||||||||||
Luminal A | 166 (34.1) | 11 (2.3) | 310 (63.7) | 337 (66.1) | 94 (18.4) | 79 (15.5) | 195 (55.6) | 105 (29.9) | 51 (14.5) | 24 (4.9) | 25 (5.1) | 442 (90.0) |
Luminal B | 72 (22.4) | 4 (1.2) | 246 (76.4) | 274 (79.2) | 47 (13.6) | 25 (7.2) | 137 (55.0) | 84 (33.7) | 28 (11.2) | 31 (9.4) | 18 (5.5) | 280 (85.1) |
HER2-OE | 31 (29.2) | 2 (1.9) | 73 (68.9) | 78 (69.0) | 31 (27.4) | 4 (3.5) | 32 (49.2) | 22 (33.8) | 11 (16.9) | 42 (39.6) | 21 (19.8) | 43 (40.6) |
TNBC | 48 (32.4) | 4 (2.7) | 96 (64.9) | 121 (77.1) | 20 (13.2) | 16 (10.7) | 63 (66.3) | 21 (22.1) | 11 (11.6) | 93 (62.4) | 23 (15.4) | 33 (22.1) |
BLBC | 16 (24.2) | 2 (3.0) | 48 (72.7) | 63 (90.0) | 3 (4.3) | 4 (5.7) | 24 (60.0) | 11 (27.5) | 5 (12.5) | 46 (67.6) | 13 (19.1) | 9 (13.2) |
5NP | 32 (3.9) | 2 (2.4) | 48 (58.5) | 58 (66.7) | 17 (19.5) | 12 (13.8) | 39 (70.9) | 10 (18.2) | 6 (10.9) | 47 (58.0) | 10 (12.3) | 24 (29.6) |
p-value | 0.012 | < 0.001 | 0.347 | < 0.001 | ||||||||
Proportion of positively stained cells | ||||||||||||
Mean | 51.9 | 11.4 | 15.7 | 65.9 | ||||||||
Median | 70 | 0 | 1 | 90 |
HR | 95% CI for HR | p-value | |
---|---|---|---|
DFS | |||
Age | 0.974 | 0.952-0.997 | 0.025 |
pT | 1.923 | 1.322-2.796 | 0.001 |
pN | 1.984 | 1.544-2.550 | < 0.001 |
PELP1 status | 1.403 | 1.079-1.851 | 0.012 |
BCSS | |||
Age | 0.970 | 0.946-0.996 | 0.023 |
pT | 2.669 | 1.713-4.159 | < 0.001 |
pN | 1.717 | 1.305-2.259 | < 0.001 |
PELP1 status | 1.443 | 1.075-1.937 | 0.015 |
Values are presented as number (%). PELP1, proline, glutamic acid, and leucine-rich protein 1; RCC, renal cell carcinoma. A statistical significant difference (p < 0.001) was found in the expression rate between breast, lung, and ovarian cancers.
Values are presented as number (%). PELP1, proline, glutamic acid, and leucine-rich protein 1; LVI, lymphovascular invasion; FF, fibrotic focus; HER2-OE, human epidermal growth factor receptor 2 overexpression; BLBC, basal like breast cancer; 5NP, quintuple negative; SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; EGFR, epidermal growth factor receptor; CK, cytokeratin; MGB, mammaglobin; GCDFP-15, gross cystic disease fluid protein 15.
Values are presented as number (%). PELP1, proline, glutamic acid, and leucine-rich protein 1; GCDFP-15, gross cystic disease fluid protein 15; MGB, mammaglobin; HER2-OE, human epidermal growth factor receptor 2 overexpression; TNBC, triple negative breast cancer; BLBC, basal like breast cancer; 5NP, quintuple negative.
Backwald method was used for the analysis. Factors included in the initial steps included age, grade, LVI, pT, pN, Ki67, HER2, AR, and PELP1 status. LVI, Ki67, HER2, AR and PELP1 were analyzed as categorical variables. The absence of LVI, Ki67 low, HER2 negativity, AR negativity, and PELP1 low status were used as references in their categories. DFS, disease free survival; BCSS, breast cancer specific survival; HR, hazard ratio; CI, confidence interval; PELP1, proline, glutamic acid, and leucine-rich protein 1; LVI, lymphovascular invasion; HER2, human epidermal growth factor receptor 2; AR, androgen receptor.